Journal
PHARMACEUTICS
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13081120
Keywords
salinomycin; nanoparticles; cancer stem cells; cancer; drug delivery system; nanotechnology; nanosystems
Categories
Funding
- Romanian Ministry of Education and Research, CNCS-UEFISCDI [PN-III-P1-1.1-PD-2019-0781]
Ask authors/readers for more resources
Cancer stem cells (CSCs) are resistant to conventional therapies, making salinomycin a promising new candidate that selectively targets CSCs. Nanotechnology allows for efficient delivery of salinomycin to tumors, reducing collateral damage and enhancing therapeutic outcomes.
Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available